ALSO NOTED: Ranbaxy gets approval; FDA warns nursing mothers on codeine;

> Ranbaxy Pharmaceuticals got the FDA thumbs-up on its generic version of the hydrocodone-and-acetaminophen combo marketed by others as Vicodin and Lorcet, among other names. Total 2006 sales for the combination pills was $390.6 million. Release

> The FDA is warning nursing mothers who take the painkiller codeine to watch for signs of overdose--such as excess drowsiness--in their babies. Up to 10 percent of white women and 3 percent of black women have a particular gene that concentrates narcotics into their breast milk. Report

> Bayer Healthcare Pharmaceuticals and Onyx Pharmaceuticals got their liver cancer treatment Nexavar onto the FDA fast track. The agency has accepted the companies' app for Priority Review. The drug already is approved for use against kidney cancer. Release

> China Shenghuo Pharmaceutical Holdings posted a 29.3 percent increase in second-quarter profits, to $1.3 million, on sales of $6.4 million. Report

And Finally... A new frontier in diabetes treatment could be a big boon not only for patients, but also for drug makers who supply statins and other heart-related remedies. Article

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.